Exclusive Interview With Oramed Pharmaceuticals Inc. CEO, Nadav Kidron on www.Wallst.Net
19 April 2007 - 12:23AM
PR Newswire (US)
JERUSALEM, April 18 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTC:ORMP) (BULLETIN BOARD: ORMP) (FTSE: OJU)
invites everybody to join Nadav Kidron on http://www.wallst.net/ to
discuss the future of Oramed Pharmaceuticals Inc., and update the
investment community on the present status of the company. The
interview will take place at 3pm Eastern time on Thursday, April
19. It will be broadcast live on their website and then archived
into their records for future reference. If you have any specific
questions to be asked, please email them to and they will be
forwarded on Thursday morning to the interviewer. To hear the
interview in its entirety, please visit http://www.wallst.net/ and
click on "Interviews". The interview can be accessed either by
locating the Company's ticker symbol (ORMP) under the appropriate
exchange (OTCBB) on the left-hand column of the "Interviews"
section of the site, or by entering the Company's ticker symbol in
the Search Archive window. CEO Nadav Kidron stated, "I look forward
to hearing a public response to our company's efforts and successes
over the past year." About Oramed Pharmaceuticals, Inc: Oramed
Pharmaceuticals Inc. is an Israeli company focused on the
development of oral delivery solutions based on proprietary
technology. Diabetes is one of the most rapidly growing diseases in
the world and is one that requires constant and often unpleasant
monitoring and drug therapy regimen. Oramed is currently developing
an orally ingestible soft gel insulin capsule for the treatment of
diabetes. The Company is also pursuing the development of oral
delivery solutions for other drugs and vaccines. For more
information on Oramed Pharmaceuticals please visit our website at
http://www.oramedpharma.com/ Legal Notice Regarding Forward Looking
Statements This news release contains statements, which may
constitute "forward- looking statements". Those statements include
statements regarding the intent, belief or current expectations of
Oramed as well as the assumptions on which such statements are
based. Forward-looking statements in this release include: that we
are currently developing an orally soft gel insulin capsule for the
treatment of diabetes; and that we are also pursuing the
development of oral delivery solutions for other drugs and
vaccines. Factors which may significantly change or prevent our
forward looking statements from fruition include that we may be
unsuccessful in developing any products; we may be unable to raise
funds and resources to pursue research and development; we may be
unable to successfully defend our patents from infringement by
third parties, there is a risk that our patents may be subsequently
shown to be invalid or infringe the patents of others; we may be
unable to attract or retain our key employees, consultants and
advisors, our products may never gain FDA or other regulatory body
approval for human consumption and we may be unable to successfully
commercialize our future products. Readers should refer to our most
recent 10-KSB filed on Edgar and the 8-K announcing our acquisition
of the Oramed technology filed March 8, 2006. DATASOURCE: Oramed
Pharmaceuticals, Inc. CONTACT: Vinisha Agnihotri of Oramed
Pharmaceuticals, Inc., +1-646-467-2252, Web site:
http://www.oramedpharma.com/ http://www.wallst.net/
Copyright